Rivastigmine For Methamphetamine Dependent Individuals
Completed · Phase 1
Conditions studied: Substance-Related Disorders
In brief
Methamphetamine abuse has been steadily increasing over the past decade. Rivastigmine is a medication that may be helpful in treating methamphetamine dependence. The purpose of this study is to evaluate the effectiveness of rivastigmine in treating methamphetamine dependent individuals.
Key facts
- Study ID
- NCT00158210
- Run by
- National Institute on Drug Abuse (NIDA)
- People needed
- 18
- Starts
- 2006-05-01
- Expected to finish
- 2007-03-01
- Last updated by the study team
- 2017-01-12
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Speaks English
- Not seeking treatment for methamphetamine dependence at study entry
- Meets DSM-IV criteria for methamphetamine abuse or dependence
- Smokes or intravenously uses methamphetamine
- Resting pulse between 50 and 90 beats per minute within 2 days prior to study entry
- Systolic blood pressure between 85 and 150 mmHg and diastolic blood pressure between 45 and 90 mmHg within 2 days prior to study entry
- Electrocardiogram demonstrating normal sinus rhythm, normal conduction, and no clinically significant arrhythmias
- Medical history and brief physical examination demonstrating no clinically significant contraindications for study participation
You may not qualify if…
- History or evidence of seizures or brain injury
- Previous adverse reaction to methamphetamine
- Neurological or psychiatric disorders (e.g., psychosis, bipolar illness, or major depression)
- Organic brain disease or dementia
- History of any psychiatric disorder that requires ongoing treatment or that would make study compliance difficult
- History of suicide attempts within the 3 months prior to study entry
- Heart disease or high blood pressure
- Family history of early cardiovascular morbidity or mortality
- Untreated or unstable medical illness, including neuroendocrine, autoimmune, liver, kidney, or active infectious disease
- HIV infected
- AIDS-defining illness
- Currently taking antiretroviral medication
- Pregnant or breastfeeding
- Unwilling to use an adequate method of contraception for the duration of the study
- History of respiratory illness (e.g., asthma, chronic coughing, and wheezing)
- Currently using alpha or beta agonists, theophylline, or other sympathomimetics
Where it is running
- University of California - Los Angeles — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.